Tisseel VH

Drug Overview

In the complex field of hematology and surgical medicine, the ability to control bleeding effectively is a cornerstone of patient safety and successful outcomes. Tisseel VH is a sophisticated medical product categorized as a Fibrin Sealant. It is a highly specialized BIOLOGIC that mimics the body’s natural blood-clotting process to achieve rapid and reliable closure of wounds and surgical sites.

Unlike traditional methods that rely solely on mechanical closure, Tisseel VH provides a chemical and biological seal. It is a two-component system that, when combined, creates a flexible, white, rubbery mass that adheres to the tissue, providing both hemostasis (the stopping of blood flow) and tissue gluing.

• Generic Name: Fibrin Sealant (Human)
• US Brand Names: Tisseel, Tisseel VH, Tisseel VH S/D
• Route of Administration: Topical application only (Never for injection into blood vessels)
• FDA Approval Status: FDA-approved for use as an adjunct to hemostasis and as a tissue glue in a wide variety of surgical procedures.
  
  Learn essential facts about Tisseel VH. Discover its key medical uses, vital health benefits, potential side effects, and exact patient dosage.

What Is It and How Does It Work? (Mechanism of Action)

Tisseel VH functions by replicating the final stage of the body’s natural coagulation cascade. To understand its action, one must look at how the body normally stops a bleed. When a blood vessel is injured, a series of chemical reactions occur, culminating in the conversion of a soluble protein called fibrinogen into an insoluble protein mesh called fibrin.

As a BIOLOGIC, Tisseel VH consists of two primary components kept in separate syringes within a single applicator:

1. Sealer Protein Solution: This contains highly concentrated human fibrinogen and Fibronectin, along with Factor XIII and Aprotinin (which prevents the clot from breaking down too quickly).
2. Thrombin Solution: This contains human thrombin and calcium chloride.

At the molecular and hematological level, when these two solutions are mixed during application, the thrombin acts as an enzyme that immediately cleaves the fibrinogen. This creates fibrin monomers that spontaneously join together to form a sticky, three-dimensional mesh. Simultaneously, the Thrombin activates Factor XIII in the presence of calcium, which cross-links the fibrin strands. This cross-linking transforms the soft mesh into a mechanically stable, insoluble fibrin clot.

This process provides profound hemorrhage risk reduction by creating a localized, stable “plug” that adheres to the wound surface. It bypasses the earlier, more complex steps of the coagulation cascade, making it effective even in patients with certain clotting deficiencies or those who have interference from vitamin K-dependent factors.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Tisseel VH is for use as an adjunct to hemostasis in surgeries where standard surgical techniques (such as sutures, staples, or electrocautery) are insufficient. In the hematology context, it is used to stop oozing from small blood vessels and capillaries. Additionally, it is FDA-approved as a tissue glue for the sealing of colostomies, the closure of fistulas, and for adhering skin grafts to burned or injured areas.

Other Approved & Off-Label Uses

Specialists across various disciplines utilize Tisseel VH for its versatile sealing properties:

• Cardiovascular Surgery: Sealing of prosthetic vascular grafts and suture lines.
• Neurosurgery: Providing a watertight seal of the dura mater (the brain’s outer lining) to prevent cerebrospinal fluid leaks.
• Splenic and Hepatic Surgery: Managing bleeding on the porous surfaces of the liver or spleen where sutures might tear the tissue.
• Gastrointestinal Surgery: Reinforcing staple lines to prevent leaks of bowel contents.
• Oncological Resections: Sealing lymphatic vessels after tumor removal to prevent the buildup of lymph fluid (seroma).

Dosage and Administration Protocols

The “dosage” of Tisseel VH is not based on weight but rather on the surface area of the tissue that requires treatment. The amount used depends on the size of the wound and the thickness of the film required to achieve hemostasis or gluing.

Important Adjustments:

• Tissue Moisture: The surface of the tissue should be as dry as possible before application. Excess blood or fluid can dilute the sealant and weaken the bond.
• Administration Method: It is often applied via a specialized spray tip or a dual-syringe applicator. If spraying, the surgeon must maintain a specific distance (usually 10 to 15 cm) and a specific pressure (not exceeding 20 psi) to avoid air embolism.
• Maximum Infusion Rates: Not applicable, as this is a topical agent. However, application speed should be consistent to ensure even film thickness.
• Renal/Hepatic Insufficiency: No dose adjustments are required, as the components are naturally occurring proteins that are absorbed locally and broken down by the body’s normal fibrinolytic system.

Clinical Efficacy and Research Results

Clinical research spanning from 2020 to 2026 has reaffirmed Tisseel VH as a high-performance BIOLOGIC. In large-scale randomized trials involving cardiovascular and liver surgeries, Tisseel VH demonstrated a significant reduction in the “time to hemostasis” compared to traditional gauze pressure or other mechanical methods.

Numerical data from these studies indicate that Tisseel VH can achieve complete bleeding control in over 90% of surgical sites within three to five minutes of application. Furthermore, recent data from 2024 has highlighted its efficacy in reducing post-operative complications in oncological surgeries. For instance, in patients undergoing breast cancer surgery with lymph node removal, the use of Tisseel VH led to a 30% reduction in the total volume of drained fluid, allowing for earlier removal of surgical drains and shorter hospital stays.

Current research also emphasizes its role in “bloodless surgery” protocols, where it is used to minimize the need for blood transfusions by providing superior localized control of micro-vascular bleeding.

Safety Profile and Side Effects

Black Box Warning

There is currently no Black Box Warning for Tisseel VH. However, there are critical warnings regarding its administration.

Common side effects (>10%)

Because Tisseel VH is used during major surgery, it is often difficult to separate its effects from the surgery itself. However, common reactions include:

• Post-operative fever (pyrexia)
• Procedural pain
• Mild nausea

Serious adverse events

• Anaphylaxis/Hypersensitivity: As a human-derived BIOLOGIC, severe allergic reactions can occur, particularly if the patient has had prior exposure to fibrin sealants or bovine aprotinin.
• Thromboembolism: If the sealant is accidentally injected into a blood vessel, it can cause life-threatening clots, leading to stroke or heart attack.
• Air Embolism: If the spray applicator is used at a pressure higher than recommended or too close to the tissue, air can be forced into the bloodstream.
• Viral Transmission: Although rigorous screening and vapor heating (VH) processes are used to inactivate viruses, the theoretical risk of transmitting infectious agents remains as it is a human plasma-derived product.

Management Strategies

Healthcare teams monitor patients’ vital signs closely during application. If a drop in blood pressure or signs of an allergic reaction (rash, wheezing) occur, the application is stopped immediately, and emergency protocols, including epinephrine or antihistamines, are initiated. To prevent air embolism, surgeons strictly follow pressure guidelines and use CO2 instead of compressed air when possible.

Research Areas

In the 2025-2026 research landscape, scientists are focusing on “Smart Delivery” systems for Tisseel VH. This includes the development of laparoscopic and robotic-assisted sprayers that allow for precise application in minimally invasive surgeries.

Another active research area is the combination of Tisseel VH with IMMUNOTHERAPY agents. Researchers are investigating if the fibrin mesh can act as a “slow-release scaffold” for cancer-fighting drugs or growth factors, keeping the treatment localized to the tumor site after a surgical resection. Furthermore, clinical trials are ongoing to evaluate its effectiveness in treating complex anal fistulas, aiming to improve healing rates in chronic inflammatory conditions.

Disclaimer: The research mentioned regarding the development of “Smart Delivery” systems for robotic-assisted surgery and the investigation of Tisseel VH as a “slow-release scaffold” for immunotherapy agents is an active area of investigation in 2026. While these innovations aim to enhance precision and therapeutic localization, their specific clinical protocols and expanded indications are distinct from the current FDA-approved use of Tisseel VH as an adjunct to hemostasis and tissue gluing.

Patient Management and Practical Recommendations

Pre-treatment Tests

Since Tisseel VH is used during surgery, standard pre-operative diagnostics are essential:

• Complete Blood Count (CBC): To assess baseline platelet levels.
• Coagulation Profile: Testing PT/INR and aPTT to understand the patient’s natural clotting baseline.
• Allergy History: Specifically screening for previous exposure to aprotinin or fibrin sealants.

Precautions during treatment

• Vigilance for Embolism: The surgical team must ensure the drug is applied to the surface and not near open, high-pressure vessels.
• Monitoring of Transfusion Triggers: While Tisseel VH reduces bleeding, the hematologist must monitor if the patient still reaches the threshold (trigger) for a blood transfusion during complex procedures.

“Do’s and Don’ts” List

• DO inform your surgeon if you have a known allergy to bovine products, as some versions contain bovine aprotinin.
• DO notify your medical team if you have ever had a reaction to a blood product transfusion in the past.
• DON’T worry about the sealant being removed; Tisseel VH is biodegradable and will be completely absorbed by your body over 2 to 4 weeks.
• DON’T stop taking your regular medications before surgery unless explicitly instructed by your hematologist or surgeon.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Tisseel VH is a regulated medical product used exclusively in hospital settings. Always consult your surgeon or a specialist in hematology to discuss the risks, benefits, and surgical options tailored to your specific health condition.